Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage

A legfontosabb adatok

Ki végzi
DALIM TISSEN Co., Ltd.
Hol
Dél-Korea5 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
194 fő, tervezett
Kezdés
2025. júl. 3.
Várható befejezés
2027. jún.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • CartiPRO
  • Synovian®
A regiszteradat frissítve
2026. október 5.

Ki vehet részt

Életkor
19 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 43 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 19 years and older
  • Diagnosed with unilateral or bilateral knee osteoarthritis according to American College of Rheumatology (ACR) criteria, with at least 3 of the following 6 features:; Age ≥50 years; Morning stiffness <30 minutes; Crepitus on active motion; Bony tenderness; Bony enlargement; No palpable warmth
  • Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months prior to screening or at screening visit
  • Weight-bearing pain Visual Analogue Scale (VAS) score ≥40 mm in at least one knee joint at screening
  • Able to walk without assistive devices (walkers or canes), OR if using a walking aid routinely for past 6 months, able to continue using the same device throughout the study
  • Able to understand and complete efficacy assessment questionnaires
  • Willing and able to provide written informed consent

Ki nem vehet részt

  • History of myocardial infarction, congestive heart failure, other serious cardiac disease, or uncontrolled hypertension (≥140/90 mmHg despite treatment with ≥3 antihypertensive agents)
  • Cancer diagnosis within 5 years prior to screening
  • Surgical procedures (including arthroscopy) on target knee within 1 year (surgery on contralateral knee or hip may be exclusionary if it could affect target knee assessment)
  • Intra-articular corticosteroid injection into target knee within 12 weeks
  • Systemic corticosteroid use within 4 weeks (topical and inhaled corticosteroids permitted)
  • Surgery or radiation therapy to knee joint within 12 weeks, or not fully recovered from side effects
  • Immunosuppressive therapy (e.g., Cyclosporine A, Azathioprine) within 6 weeks
  • Prohibited concomitant medications within 2 weeks (unless washout period is adequate)
  • Anticoagulants (e.g., warfarin, NOACs), antiplatelet agents (e.g., aspirin >100 mg/day, clopidogrel; low-dose aspirin ≤100 mg/day permitted), thrombolytic agents (e.g., urokinase, alteplase), or Vitamin E >1000 IU/day within 2 weeks (unless adequate washout)
  • Habitual use (≥3 months) of psychoactive drugs or narcotic analgesics that may affect pain perception
  • Planned cell therapy or gene therapy to target joint
  • Known hypersensitivity to investigational product or its components
  • Women or men of childbearing potential unwilling to use acceptable contraception during study (acceptable methods: intrauterine device, tubal ligation, sterilization surgery, condom or diaphragm with spermicide, natural family planning)
  • Chronic inflammatory joint disease (e.g., rheumatoid arthritis)
  • Inflammatory joint disease (e.g., septic arthritis)
  • Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic disease
  • Painful musculoskeletal conditions (e.g., Sudeck's atrophy, Paget's disease, herniated intervertebral disc)
  • Polyarticular disease with severe osteoarthritis in other joints (e.g., hip) that may affect knee pain evaluation
  • History of autoimmune disease
  • Active infection requiring parenteral antibiotics
  • History of psychiatric disorder or epilepsy
  • History of cell therapy or gene therapy to target joint
  • Dermatological disease at injection site or site deemed unsuitable for injection
  • Cognitive impairment or dementia preventing informed consent
  • Any other condition that makes the subject unsuitable for study participation per investigator judgment
  • Uncontrolled type 1 or type 2 diabetes mellitus (HbA1c >7%)
  • Abnormal laboratory values at screening:
  • ALT, AST, BUN, or serum creatinine >2× upper limit of normal
  • Body Mass Index (BMI) ≥32 kg/m²
  • Radiographic evidence of definite loss of patellofemoral joint space
  • Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent
  • Intra-articular injections (e.g., hyaluronic acid) into knee joint within 6 months
  • Engaged in high-intensity aerobic or heavy anaerobic exercise that may affect the knee joint
  • Ligament instability of Grade II or higher in target knee (Grade 0: none; Grade I: 0-5 mm; Grade II: 5-10 mm; Grade III: >10 mm)
  • Pregnant or breastfeeding women
  • Participation in another clinical trial within 4 weeks

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.

A vizsgálat 2 csoportja

  • Study GroupA vizsgált kezelés

    Group applied with CartiPRO

    Kezelés: CartiPRO

  • Control groupMár használt kezelés, összehasonlításként

    Group applied with Synovian®

    Kezelés: Synovian®

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Long-term Efficacy and Safety of CartiPRO Injection to Alleviate Knee Pain in Patients With Osteoarthritis and/or Diverse Cartilage Defects: a Multicenter, Single-blind, Randomized, Non-inferiority, Sponsor Initiated Trial
A regiszteradat frissítve
2026. október 5.